Bakgrund: IBD är en kronisk inflammatorisk tarmsjukdom som innefattar sjukdomarna ulcerös kolit och Crohns sjukdom. Sjukdomen har ökat kraftigt i förekomst de senaste tre decennierna, även i Sverige. En person som har en kronisk sjukdom får en påverkad tillvaro och behöver stöd utöver bara kunskap om sjukdomen för att kunna hantera den. Professionell attityd och empati är viktiga aspekter för att skapa ömsesidigt förtroende och respektfull vård för personer med IBD. Syfte: Litteraturstudiens syfte var att belysa personers (≥18 år) upplevelser av att leva med inflammatorisk tarmsjukdom (IBD). Metod: En litteraturstudie med kvalitativ ansats, som omfattade 11 vetenskapliga artiklar med kvalitativ metodik, genomfördes. Databaserna CINAHL och PubMed användes för databassökning. Analysen genomfördes som en stegvis process inspirerad av innehållsanalys. Resultat: Personernas upplevelse av att leva med IBD sammanställdes i två kategorier; ‘Upplevelser ur ett inre perspektiv’ och ‘Upplevelser ur ett relationellt perspektiv’. Kategorierna delades därefter in i nio subkategorier; ‘Oförutsägbarhet och kontrollförlust’, ‘Oro för framtiden’, ‘Kroppsbild och stigma’, ‘Fysiska påfrestningar’, ‘Optimism’, ‘Sociala situationer’, ‘Familj och partner’, ‘Arbete samt ‘Sjukvård’. Konklusion: Personer med IBD upplever både fysiska och psykiska påfrestningar som kräver en helhetssyn i omvårdnaden. En individanpassad omvårdnad är avgörande för att upprätthålla förtroendet för vården och främja positiva resultat för personens behandling och hälsa. Sjuksköterskor bör vara lyhörda för de individuella behoven och ta hänsyn till de psykiska påfrestningar som sjukdomen kan bidra till. Det är också viktigt att skapa en trygg miljö för personerna, då sjuksköterskan kan fungera som en stödjande faktor vid sociala problem. Litteraturstudien visar därmed att omvårdnad spelar en betydande och värdefull roll i personers upplevelser av att leva med IBD. / Background: IBD is a chronic inflammatory bowel disease that includes ulcerative colitis and Crohn disease. It has significantly increased in incidence over the past three decades, in Sweden as well. A person with chronic illness experiences an impacted life and requires support beyond just knowledge of the disease in order to be able to manage it. Professional attitude and empathy are important aspects to create mutual trust and respectful care for people with IBD. Aim: The aim was to illuminate people’s (≥18 years) experiences of living with inflammatory bowel disease (IBD). Method: A literature review with a qualitative approach, which included 11 scientific articles with qualitative methodology. The databases CINAHL and PubMed were used for the database searching. The analysis was conducted as a stepwise process inspired by content analysis. Results: The people’s experience of living with IBD was compiled into two categories; ‘Experiences from an inner perspective’ & ‘Experiences from a relational perspective’. The categories were then divided into 9 subcategories; ‘Unpredictability and loss of control’, ‘Anxiety about the future’, ‘Body image and stigma’, ‘Physical stress’, ‘Optimism’, ‘Social situations’, ‘Family and partner’, ‘Work’ and ‘Healthcare’. Conclusion: People with IBD experience both physical and psychological stress, which requires a holistic view in nursing. Individualized care is crucial to maintaining trust and promoting positive outcomes for a person's treatment and health. Nurses should be attentive to individual needs and consider the psychological impacts of the disease. Additionally, creating a safe environment is important, as nurses can act as a supportive factor in case of social problems. The literature review highlights the significant and valuable role of nursing care in the experiences of individuals living with IBD.

Introduction Inflammatory bowel disease (IBD) and its complications have been well-established. The literature shows an association between IBD and decreased bone mineral density in the adult population. However, most studies have reported an association between IBD and osteoporosis, while the risk of fractures has not been well-studied. The aim of this meta-analysis is to summarize the best available evidence regarding IBS and osteoporotic fractures. Methods A review of the literature using the MEDLINE and EMBASE databases was performed during November 2017. We included cross-sectional and cohort studies that reported the relative risks, odds ratios, and hazard ratios comparing the risk of developing osteoporotic fractures among patients with IBD patients, both ulcerative colitis (UC) and Crohn's disease (CD), versus patients without IBD as controls. The pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using the generic inverse-variance method. Results After a review of the literature, seven studies fulfilled the eligibility criteria established during the analysis. A significant association was found between IBD and osteoporosis, with a pooled OR of 1.32 (95% CI, 1.2 - 1.4). Low heterogeneity among the studies was found, I=42.3. No publication bias was found using the Egger regression test p=0.18. Sensitivity analysis showed that the inclusion of data on children by Kappelman et al. (2007) did not change the results. Conclusion A significant association between IBD and the risk of developing osteoporotic fractures was observed in this study. There is a 32% increased risk, which is consistent with different cohort studies previously done.

Bakgrund: Inflammatoriska tarmsjukdomar är samlingsnamnet för Crohns sjukdom och Ulcerös kolit. Insjuknandet sker i 20–30 års ålder och sjukdomen är vanligast i västvärlden. Skillnaden mellan varianterna är lokalisation, symtom och riskfaktorer. Sjukdomen är kronisk och därför har omvårdnaden en särskilt betydelsefull roll främst för att skapa goda förutsättningar för att leva med och inte kämpa emot sjukdomen. Syfte: Att beskriva personers upplevelser av inflammatorisk tarmsjukdom. Metod: Metoden som har använts är en litteraturöversikt som är baserad på originalartiklar från kvalitativa studier funna ur databaserna Cinahl Complete och PubMed. Vetenskapliga artiklar som svarade på litteraturöversiktens syfte har analyserats och syntetiserats för att svara på syftet. Resultat: De 10 valda vetenskapliga artiklarna resulterade i fyra kategorier vilka är: Sociala begränsningar och isolering, Relationernas betydelse, Ändå en mening med livet och acceptans samt Arbets-och studierelaterade konsekvenser. Sammanfattning: Till följd av sjukdomen upplevde personer med IBD ett begränsat vardagligt liv, socialt liv och ekonomiska problem. Planering av vardagen har varit mycket tids- & energikrävande. Personerna upplevde inte enbart negativa konsekvenser utan sjukdomen medförde att de fick se livet på ett positivt sätt, hittade mening med livet och förbättrade sin livskvalitet. Sjuksköterskans stödjande roll har varit att skapa en god vårdrelation utifrån ett personcentrerat förhållningssätt och  tillgodose deras vårdbehov. / Background: Inflammatory bowel diseases are a term used to describe Crohns disease and ulcerative colitis. Patients who develop IBD are usually diagnosed between the age of 20 - 30 years old and it is most common in western countries. The difference between Crohns disease and ulcerative colitis are the location in the bowels, symptoms and risk factors. IBD is a chronic disease and should therefore be treated accordingly to relieve symptoms and prevent them from returning. Aim: To describe the experience of inflammatory bowel disease. Method: The method that has been used is based on a literature review from original  articles of qualitative studies found in Cinahl complete and PubMed databases. The scientifical articles also responded to the purpose of the literature review which has been analysed and incorporated to answer the purpose. Results: The 10 different scientific articles have been selected to be used and then divided into four different categories which are the following: social limitations and isolation, importance of relationships, meaning of life and acceptance, and work- and study related consequences. Conclusion: As a result of the disease, people with IBD experienced a limited everyday life, social life and financial problems. Planning everyday life has been very time and energy consuming. The people not only experienced negative consequences, but the disease meant that they got to see life in a positive way, found meaning in life and improved their quality of life. The nurse's supportive role has been to create a good care relationship based on a person-centered approach and meet their care needs.

No description available.

Commercial and homemade diets are currently used to treat many canine patients with acquired disorders of the colon. Clinically, the efficacy of diets has been found to be unpredictable. Only one study to date has evaluated the effect of diet on the colonic mucosa. This study showed that diet did not observably alter the colonic mucosa of normal dogs, when biopsy samples were evaluated by light microscopy. The effect of diet on colonic ultrastructure in the dog, using transmission electron microscopy, has not previously been investigated. To determine the effect of diet on colonic ultrastructure, cell height, cell area, microvillus height, number of microvilli/apex width and basement membrane width were measured. Ten cells per animal were evaluated. Six dogs were assigned to the control group and fed the control diet for the duration of the study. Six dogs were fed each of the three test diets at four week intervals. The test diets used included a high fiber diet, a hypoallergenic diet and a highly digestible diet. These diets were selected because they are the diets most often recommended for the canine patient with colonic disorders. The value for cell height for the highly digestible group was significantly greater than the other groups, as measured by ANOV A and Duncan's multiple comparison test. No other significant differences were found. The biological relevance of a significantly different value for cell height alone is difficult to evaluate, as other parameters that would indicate an alteration in maturation or proliferation of the colonic epithelial cells did not change. value for cell height alone is difficult to evaluate, as other parameters that would indicate an alteration in maturation or proliferation of the colonic epithelial cells did not change. Therefore, we conclude that commercial diets do not have an effect on the colonic ultrastructure of normal dogs. Although no effect of diet was found, this study does provide morphologic measurements that can be used as a basis for future ultrastructural studies of the colonic mucosa. / Master of Science

No / The interleukin-2-deficient (IL-2¿/¿) mouse model of ulcerative colitis was used to test the hypothesis that colonic epithelial cells (CEC) directly respond to bacterial antigens and that alterations in Toll-like receptor (TLR)-mediated signaling may occur during the development of colitis. TLR expression and activation of TLR-mediated signaling pathways in primary CEC of healthy animals was compared with CEC in IL-2¿/¿ mice during the development of colitis. In healthy animals, CEC expressed functional TLR, and in response to the TLR4 ligand LPS, proliferated and secreted the cytokines IL-6 and monocyte chemoattractant protein-1 (MCP-1). However, the TLR-responsiveness of CEC in IL-2¿/¿ mice was different with decreased TLR4 responsiveness and augmented TLR2 responses that result in IL-6 and MCP-1 secretion. TLR signaling in CEC did not involve NF-B (p65) activation with the inhibitory p50 form of NF-B predominating in CEC in both the healthy and inflamed colon. Development of colitis was, however, associated with the activation of MAPK family members and upregulation of MyD88-independent signaling pathways characterized by increased caspase-1 activity and IL-18 production. These findings identify changes in TLR expression and signaling during the development of colitis that may contribute to changes in the host response to bacterial antigens seen in colitis.

Doctor of Philosophy / In healthy individuals, the autoimmune system is the body's natural defense against foreign materials and organisms. The main tools utilized for this defense mechanism are immune cells. However, in patients suffering from autoimmune diseases, the autoimmune system is overactive resulting in its attack on healthy cells, which leads to reduced or eliminated function of the targeted organs. To suppress these overreactive immune responses, pharmaceutical intervention is needed. An integral part of autoimmune response is the lipid sphingosine-1-phosphate (S1P). Interactions of S1P with its response-inducing receptors prompts the release of immune cells, lymphocytes in particular, from lymph tissue to migrate and participate in the invoked immune response. The pharmaceutical industry has produced five FDA approved drugs that disrupt this S1P-receptor interaction by blocking the receptor to reduce the autoimmune response in patients suffering from autoimmune diseases such as multiple sclerosis and ulcerative colitis. However, these treatments had adverse side effects on the cardiovascular system due to the presence of S1P receptors in the heart. Due to this, there is attraction to target a different node of the S1P signaling pathway to avoid these side effects while still suppressing the immune response. A node that is a viable target for therapeutic target that has recently become the focus of medicinal chemistry campaigns is the transporter protein spinster homolog 2 (Spns2). This protein is responsible for the transport of S1P from intracellular space to extracellular space to interact with its receptors and induce the immune response. Recently, our group has developed several effective inhibitors of Spns2. In this dissertation, several improvements of previously reported inhibitors are revealed. The pinnacle of this work is the development of 4.22v that is optimized to have drug-like properties for testing in mice. Administration of 4.22v to mice resulted in reduced circulating lymphocytes and without showing signs of toxicity following chronic dosing for 14 days. These results suggest that 4.22v is a potential drug candidate and is currently undergoing further biological evaluation.

Background: Inflammatory Bowel Disease (IBD) is a group of chronic gastrointestinal diseases with a relapsing nature. The two main types are Crohn’s disease (CD) and ulcerative colitis (UC). Both CD and UC patients experience very similar and distressing symptoms: acute abdominal pain, vomiting, malnutrition, fever, fatigue, diarrhoea and rectal bleeding. These symptoms are disabling and have a severe impact on physical and psychosocial wellbeing. Around 30% of patients suffer from moderate to severe psychological distress and have difficulties coping with the illness even in remission. However, it appears that mental health is overlooked by clinicians who often focus on physical gastrointestinal symptoms only. Mindfulness-Based Cognitive Therapy (MBCT) is evidence based, group psychological intervention that has been successful in reducing depression and anxiety scores in patients with depression while improving overall quality of life. However, MBCT has never been tested in the IBD population before. PhD question: Can MBCT be used as an adjunct therapy to IBD symptom management, for improving IBD patients' general well-being and quality of life? Aims and objectives: The overall aim of the thesis was to develop and collate the evidence for a definitive randomised controlled trial (RCT) testing the effectiveness of MBCT for patients with inflammatory bowel disease (IBD). The thesis brings together six publications. The six publications were integrated into four objectives that collectively contributed in answering the overall PhD question. Results: The findings from the first three publications highlighted the disease-related concerns and psychological needs for patients with IBD. The findings from the last three publications highlighted how feasible it is to use MBCT in IBD and emphasised the IBD patients’ perspectives about MBCT. Conclusion: The thesis concluded that a definitive RCT of MBCT for IBD patients is both feasible and acceptable.

Inflammatory bowel disease encompasses a variety of heterogeneous chronic inflammatory diseases that affect the gastrointestinal tract, where Crohn’s disease and ulcerative colitis are the principal examples. The etiology of these, and many other complex human diseases, remain largely unknown and therefore pose relevant targets for novel research strategies. One such strategy is the in silico application of network theory derived methods to data sourced from publicly available repositories of e.g. gene expression data. Specifically, methods generating graphs of interconnected elements enriched by differentially expressed genes—disease modules—were inferred with data available through the Gene Expression Omnibus. Based on a previous method, the current project aimed to evaluate disease modules, combined from stand-alone inferential methods, in disease consensus modules: representing pathophenotypical motifs for the diseases of interest. The modules found to be significantly enriched by genome-wide association study inferred single-nucleotide polymorphisms, as validated using the Pathway Scoring Algorithm, were subsequently subjects for further analysis using Kyoto Encyclopedia of Genes and Genomes-pathway enrichment, and literature searches. The results of this study adheres to previous findings relating to the employed method, but lack any novelty pertaining the diseases of interest. However, the results substantiate the preceding methods’ conclusion by including parameters that increase statistical validity. In addition, the study contributed to peripheral results concerning both the methodology of consensus module methods, and the elucidation of inflammatory bowel disease etiology and disease subtype differentiation, that pose interesting subjects for future investigation.

As doenças inflamatórias intestinais (DII) - doença de Crohn e retocolite ulcerativa, são condições crônicas que, na maioria dos casos, exigem controle com terapia medicamentosa. A atenção farmacêutica (AF), definida como a provisão responsável do tratamento farmacológico, com o propósito de alcançar resultados concretos que melhorem a qualidade de vida do paciente, constitui nova forma de cuidado ao paciente, que necessita ser mais extensivamente avaliada. Este estudo teve o objetivo de avaliar a contribuição da atenção farmacêutica ao tratamento clínico de pacientes com DII em acompanhamento ambulatorial em hospital terciário. Ao longo de um ano, foi avaliado um grupo que recebeu a atenção farmacêutica (GAF; N=18) e um grupo controle (GC; N=17) não submetido aos procedimentos da AF. Os resultados da contribuição da AF foram avaliados pela comparação de diferentes variáveis entre os grupos, que foram obtidas na primeira entrevista - T(0), aos seis - T(6) e 12 - T(12) meses do estudo. Quanto aos aspectos clínicos, houve redução significativa dos índices de atividade clínica de T(6) para T(12) no GAF (mediana; variação: 2,20; 0,99 3,77 versus 1,90; 0,99 3,77; p=0,02), o que não ocorreu no GC (1,69; 0,99 3,77 versus 1,69; 0,99 3,48). No GAF, houve aumento significativo do percentual de pacientes mais aderentes ao tratamento medicamentoso (27,8% versus 72,2%; p<0,05), quando da avaliação por meio do teste de Morisky, mas não foram observadas diferenças (72,2% versus 88,9%) na adesão avaliada pelo cotejo entre medicamentos utilizados e prescrições registradas. Em ambas as formas de avaliação da adesão, tanto pelo teste de Morisky (41,2% versus 41,2%), quanto pelo confronto das medicações utilizadas e prescrições registradas (88,2% versus 82,4%), não foram observadas alterações no GC. Houve aumento significativo dos índices de conhecimento do paciente sobre o tratamento no GAF entre T(0) e T(12) (mediana; variação: 80%; 40% 100% versus 100%; 100% 100%; p0,0001), o que não ocorreu no GC (80%; 0 100% versus 80%; 60% 100%). No que se refere à qualidade de vida, avaliada pelo instrumento SF36, houve diferenças estatisticamente significativas nos dois grupos apenas no domínio de saúde mental. No GAF, houve elevação dos escores deste domínio entre T(0) e T(12) (54,0 versus 66,0; p=0,04), o que, também ocorreu no GC (60,0 versus 68,0; p=0,01). Porém, no GAF, esta mudança ocorreu mais precocemente, de T(0) para T(6) (54,0 versus 66,0; p<0,01). A AF possibilitou a identificação, em média, de 3,8 problemas relacionados ao medicamento por paciente, que em sua maioria foram resolvidos, com intervenções predominantemente focadas em orientações aos pacientes. Os pacientes do GAF, ao término do estudo, apresentaram alto grau de satisfação com a AF. Os resultados obtidos permitem concluir que a introdução de um programa de atenção farmacêutica a pacientes ambulatoriais com DII seguidos em hospital terciário trouxe contribuição positiva, proporcionando benefícios mensuráveis aos pacientes. / Inflammatory bowel diseases (IBD) Crohns disease and ulcerative colitis are chronic conditions which are usually controlled with drug therapy. Pharmaceutical care (PC), defined as the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve patients quality of life, is a new patient care modality, which needs to be more extensively evaluated. This study aimed at assessing the contribution of pharmaceutical care to the clinical treatment of outpatients with IBD assisted at a reference hospital. During one year, a group receiving pharmaceutical care (PCG; N=18) and a control group (CG; N=17), which did not undergo PC procedures, were evaluated. Results of PC contribution were assessed by comparing the two groups regarding different variables obtained in the first interview at - T(0), at six - T(6) and 12 - T(12) months of study. Regarding the clinical aspects, there was a significant decrease of clinical activity indexes from T(6) to T(12) in the PCG (median; range: 2.20; 0.99 3.77 versus 1.90; 0.99 3.77; p=0.22), but not in the CG (1.69; 0.99 3.77 versus 1.69; 0.99 3.48). In the PCG, there was a significant increase in the percentage of patients who were more compliant to drug treatment (27.8 % versus 72.2 %; p<0.05) as assessed using the Morisky scale; however, no differences in compliance rates were observed (72.2 % versus 88.9 %) by comparing drugs taken with registered prescriptions. In the CG, no differences were observed in none of the compliance assessment methods, neither by the Morisky scale (41.2% versus 41.2%), nor by comparing drugs taken with registered prescriptions (88.2% versus 81.2%). There was a significant increase in the values of an index for patients knowledge about the treatment in the PCG between T(0) and T(12) (median; range: 80%; 40 100 versus 100%; 100 100; p0,0001), but not in the CG (80%; 0 100 versus 80%; 60 100). With respect to quality of life, assessed by the SF36 scale, there were statistically significant differences in both groups only in the mental health domain. There was an increase in scores for this domain between T(0) and T(12) in both PCG (54.0 versus 66.0; p=0,04), and CG (60.0 versus 68.0; p=0,01). However, PCG had this increasing scores earlier, between T(0) and T(12) (54.0 versus 74.0; p<0,01). PC enabled the identification of a number of drug-related problems per patient (mean = 3.8), which were mostly solved by interventions predominantly focused on patient orientation. At the end of the study, patients in the PC group showed a high degree of satisfaction with the intervention. The achieved results allow concluding that the implementation of a pharmaceutical care program to outpatients with IBD followed at a tertiary hospital gave a positive contribution, providing measurable benefits to patients.